



The Board of Directors of Asker Healthcare Group AB (publ)'s statement in accordance with Chapter 19, Section 22 of the Swedish Companies Act

The financial position of the company

The financial position of the company, as of 31 December 2025, is presented in the annual report for the financial year 2025. Furthermore, the principles applied for valuation of assets, provisions and debt are presented in the annual report. The proposal regarding repurchase of own C-shares entails that the Board of Directors is authorised to acquire no more than 1,220,000 C-shares. The scope for acquiring own shares is limited by available unrestricted equity in accordance with the approved annual report 2025. As of 31 December 2025, the parent company's unrestricted equity amounted to SEK 4,470 million. As of the same date, the group's total equity attributable to shareholders of the parent company amounted to SEK 6,555 million.

The rationale of the authorisation to acquire own shares

With reference to the above and to other information that has come to the Board of Directors' knowledge, it is the opinion of the Board of Directors that the proposed authorisation to acquire own shares is justifiable with reference to the demands that the nature, scope and risks of the company's and the group's operations place on the size of the company's and the group's equity and the company's and group's consolidation needs, liquidity and overall position.

Danderyd, March 2026

Asker Healthcare Group AB (publ)

The Board of Directors